Putnam Investments LLC Has $1.74 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Putnam Investments LLC decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 1.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,561 shares of the biotechnology company’s stock after selling 957 shares during the period. Putnam Investments LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,737,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Captrust Financial Advisors increased its holdings in shares of Arrowhead Pharmaceuticals by 22.4% in the 2nd quarter. Captrust Financial Advisors now owns 1,201 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 220 shares during the period. Private Advisor Group LLC increased its holdings in Arrowhead Pharmaceuticals by 2.7% in the third quarter. Private Advisor Group LLC now owns 11,795 shares of the biotechnology company’s stock worth $390,000 after buying an additional 313 shares during the last quarter. O Shaughnessy Asset Management LLC increased its holdings in Arrowhead Pharmaceuticals by 3.5% in the second quarter. O Shaughnessy Asset Management LLC now owns 9,704 shares of the biotechnology company’s stock worth $342,000 after buying an additional 326 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in Arrowhead Pharmaceuticals by 94.6% in the first quarter. Advisors Asset Management Inc. now owns 720 shares of the biotechnology company’s stock worth $33,000 after buying an additional 350 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 1.4% in the third quarter. ProShare Advisors LLC now owns 27,721 shares of the biotechnology company’s stock worth $917,000 after buying an additional 384 shares during the last quarter. Institutional investors and hedge funds own 65.46% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 5.1 %

ARWR opened at $26.31 on Monday. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $25.54 and a 1-year high of $51.11. The stock has a market capitalization of $2.85 billion, a price-to-earnings ratio of -17.90 and a beta of 1.05. The business has a 50 day moving average of $33.79 and a 200-day moving average of $34.03.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last posted its quarterly earnings data on Monday, February 6th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $1.14 by ($1.53). The business had revenue of $62.55 million during the quarter, compared to the consensus estimate of $162.52 million. Arrowhead Pharmaceuticals had a negative net margin of 54.31% and a negative return on equity of 34.73%. The firm’s revenue was up 127.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.60) earnings per share. Equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.4 EPS for the current year.

Insider Buying and Selling

In related news, Director William D. Waddill sold 3,200 shares of the firm’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $30.00, for a total value of $96,000.00. Following the completion of the transaction, the director now directly owns 28,950 shares of the company’s stock, valued at $868,500. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director William D. Waddill sold 3,200 shares of the firm’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $30.00, for a total value of $96,000.00. Following the completion of the transaction, the director now directly owns 28,950 shares of the company’s stock, valued at $868,500. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Douglas B. Given sold 875 shares of the firm’s stock in a transaction on Monday, February 27th. The stock was sold at an average price of $32.62, for a total value of $28,542.50. Following the completion of the transaction, the director now directly owns 13,000 shares of the company’s stock, valued at $424,060. The disclosure for this sale can be found here. Insiders sold a total of 102,691 shares of company stock valued at $3,864,750 over the last ninety days. 5.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ARWR shares. SVB Leerink dropped their price objective on Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a “market perform” rating on the stock in a report on Tuesday, November 29th. B. Riley dropped their price objective on Arrowhead Pharmaceuticals from $59.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, February 8th. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, February 10th. Jefferies Financial Group lowered their price target on Arrowhead Pharmaceuticals from $92.00 to $75.00 and set a “buy” rating on the stock in a report on Tuesday, November 29th. Finally, Royal Bank of Canada lowered their price target on Arrowhead Pharmaceuticals from $83.00 to $77.00 and set an “outperform” rating on the stock in a report on Tuesday, February 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.10.

Arrowhead Pharmaceuticals Profile

(Get Rating)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.